Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).

Hooper CY, Smith WJ.

Ther Clin Risk Manag. 2012;8:131-7. doi: 10.2147/TCRM.S23247. Epub 2012 Mar 16.

PMID:
22547931
[PubMed]
Free PMC Article
2.

Telavancin: a new lipoglycopeptide for gram-positive infections.

Smith WJ, Drew RH.

Drugs Today (Barc). 2009 Mar;45(3):159-73. doi: 10.1358/dot.2009.45.3.1343792. Review.

PMID:
19436839
[PubMed - indexed for MEDLINE]
3.

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.

Barriere SL.

Future Microbiol. 2014;9(3):281-9. doi: 10.2217/fmb.14.4. Epub 2014 Jan 22.

PMID:
24450506
[PubMed - in process]
4.

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).

Dunbar LM, Tang DM, Manausa RM.

Ther Clin Risk Manag. 2008 Feb;4(1):235-44.

PMID:
18728713
[PubMed]
Free PMC Article
5.

Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.

Hegde SS, Janc JW.

Expert Rev Anti Infect Ther. 2014 Dec;12(12):1463-75. doi: 10.1586/14787210.2014.979789.

PMID:
25382700
[PubMed - in process]
6.

Telavancin: a novel lipoglycopeptide antimicrobial agent.

Attwood RJ, LaPlante KL.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2335-48. Review.

PMID:
17989443
[PubMed - indexed for MEDLINE]
7.

Telavancin: TD 6424, TD-6424.

[No authors listed]

Drugs R D. 2006;7(6):384-8. Review.

PMID:
17073522
[PubMed - indexed for MEDLINE]
8.

Telavancin: a novel lipoglycopeptide for serious gram-positive infections.

Laohavaleeson S, Kuti JL, Nicolau DP.

Expert Opin Investig Drugs. 2007 Mar;16(3):347-57. Review.

PMID:
17302529
[PubMed - indexed for MEDLINE]
9.

The role of telavancin in the treatment of MRSA infections in hospital.

Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C.

Expert Opin Investig Drugs. 2009 Apr;18(4):521-9. doi: 10.1517/13543780902845630 . Review.

PMID:
19335280
[PubMed - indexed for MEDLINE]
10.

Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.

Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA.

Expert Opin Pharmacother. 2011 Dec;12(17):2737-50. doi: 10.1517/14656566.2011.633511. Review.

PMID:
22077833
[PubMed - indexed for MEDLINE]
11.

Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.

Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME.

PLoS One. 2012;7(8):e41870. doi: 10.1371/journal.pone.0041870. Epub 2012 Aug 16. Review.

PMID:
22916113
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.

Nannini EC, Corey GR, Stryjewski ME.

Expert Rev Anti Infect Ther. 2012 Aug;10(8):847-54. doi: 10.1586/eri.12.81. Review.

PMID:
23030322
[PubMed - indexed for MEDLINE]
13.

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections.

Jafari Saraf L, Wilson SE.

Infect Drug Resist. 2011;4:87-95. doi: 10.2147/IDR.S5327. Epub 2011 Mar 10.

PMID:
21694912
[PubMed]
Free PMC Article
14.

Telavancin: a review of its use in patients with nosocomial pneumonia.

Scott LJ.

Drugs. 2013 Nov;73(16):1829-39. doi: 10.1007/s40265-013-0144-x. Review.

PMID:
24190596
[PubMed - indexed for MEDLINE]
15.

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.

Leonard SN, Rybak MJ.

Pharmacotherapy. 2008 Apr;28(4):458-68. doi: 10.1592/phco.28.4.458. Review.

PMID:
18363530
[PubMed - indexed for MEDLINE]
16.
17.

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Lodise TP, Low DE.

Drugs. 2012 Jul 30;72(11):1473-93. doi: 10.2165/11635660-000000000-00000. Review.

PMID:
22779432
[PubMed - indexed for MEDLINE]
18.

Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.

Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA.

Am J Clin Dermatol. 2008;9(4):245-54. Review.

PMID:
18572975
[PubMed - indexed for MEDLINE]
19.

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group.

Clin Infect Dis. 2011 Jan 1;52(1):31-40. doi: 10.1093/cid/ciq031.

PMID:
21148517
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk